<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">34491663</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>19</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>19</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">0973-3922</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>88</Volume>
            <Issue>3</Issue>
            <PubDate>
              <Year>2022</Year>
              <Season>May-Jun</Season>
            </PubDate>
          </JournalIssue>
          <Title>Indian journal of dermatology, venereology and leprology</Title>
          <ISOAbbreviation>Indian J Dermatol Venereol Leprol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Differential expression of interleukin-6 in leprosy reactions.</ArticleTitle>
        <Pagination>
          <StartPage>378</StartPage>
          <EndPage>379</EndPage>
          <MedlinePgn>378-379</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.25259/IJDVL_687_2021</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">10.25259/IJDVL_687_2021</ELocationID>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Sharma</LastName>
            <ForeName>Mukul</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Indian Council of Medical Research-National Institute of Research in Tribal Health, Jabalpur, Madhya Pradesh, India.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Singh</LastName>
            <ForeName>Pushpendra</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Indian Council of Medical Research-National Institute of Research in Tribal Health, Jabalpur, Madhya Pradesh, India.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016422">Letter</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Indian J Dermatol Venereol Leprol</MedlineTA>
        <NlmUniqueID>7701852</NlmUniqueID>
        <ISSNLinking>0378-6323</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015850" MajorTopicYN="Y">Interleukin-6</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007918" MajorTopicYN="Y">Leprosy</DescriptorName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009166" MajorTopicYN="N">Mycobacterium leprae</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>7</Month>
          <Day>1</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>7</Month>
          <Day>1</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>9</Month>
          <Day>8</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>20</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>9</Month>
          <Day>7</Day>
          <Hour>12</Hour>
          <Minute>52</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34491663</ArticleId>
        <ArticleId IdType="doi">10.25259/IJDVL_687_2021</ArticleId>
        <ArticleId IdType="pii">10.25259/IJDVL_687_2021</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Vilani-Moreno FR, Brito-de-Souza VN, Silva SUR, Barbosa AS, Sartori BG, Campanelli AP, et al. Increased serum levels of interleukin-6 in erythema nodosum leprosum suggest its use as a biomarker. Indian J Dermatol Venereol Leprol. 2021; 87:190-8</Citation>
        </Reference>
        <Reference>
          <Citation>Scollard DM, Adams LB, Gillis TP, Krahenbuhl JL, Truman RW, Williams DL,. The continuing challenges of leprosy. Clin Microbiol Rev. 2006; 19:338-81</Citation>
        </Reference>
        <Reference>
          <Citation>Gautam S, Sharma D, Goel A, Patil SA, Bisht D,. Insights into Mycobacterium leprae proteomics and biomarkers an overview. Proteomes. 2021; 9:7</Citation>
        </Reference>
        <Reference>
          <Citation>Singh PP, Goyal A,. Interleukin-6: A potent biomarker of mycobacterial infection. Springerplus. 2013; 2:686</Citation>
        </Reference>
        <Reference>
          <Citation>Sousa AL, Fava VM, Sampaio LH, Martelli CM, Costa MB, Mira MT, et al. Genetic and immunological evidence implicates interleukin 6 as a susceptibility gene for leprosy Type 2 reaction. J Infect Dis. 2012; 205:1417-24</Citation>
        </Reference>
        <Reference>
          <Citation>Saini C, Siddiqui A, Ramesh V, Nath I, et al. Leprosy reactions show increased Th17 cell activity and reduced FOXP3+ tregs with concomitant decrease in TGF-Î² and increase in IL-6. PLoS Negl Trop Dis. 2016; 10:e0004592</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
